Story excerpt provided by Crain’s Cleveland Business.
Written by Chuck Soder.
Pfizer plans to help Western Oncolytics move its gene therapy through Phase I clinical trials — and it could buy the company if those trials go well.
Under the agreement, Pfizer will work with the small Westlake-based company to complete animal trials and Phase I clinical trials. Afterward it would have the exclusive option to acquire the drug, according to a news release from the two companies.
The drug, which is called WO-12, is designed to fight cancer in multiple ways.
Click here to read the complete article.
Originally published July 28, 2016.